Compare WHG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | UNCY |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 141.8M |
| IPO Year | 2002 | 2021 |
| Metric | WHG | UNCY |
|---|---|---|
| Price | $17.97 | $7.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 12.2K | ★ 522.6K |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ 154.57 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $96,243,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.97 | ★ N/A |
| Revenue Growth | ★ 4.20 | N/A |
| 52 Week Low | $14.00 | $3.71 |
| 52 Week High | $18.99 | $11.00 |
| Indicator | WHG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 65.20 |
| Support Level | $17.89 | $6.60 |
| Resistance Level | $18.27 | $7.19 |
| Average True Range (ATR) | 0.49 | 0.48 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 62.31 | 95.21 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.